Ranbaxy Laboratories, which is operating under an extensive consent decree with U.S. regulators, has now run afoul of authorities in India.
The generic onslaught on Pfizer's blockbuster Lipitor started just 6 months ago, but the pain is reaching Ireland where the company is poised to cut nearly 200 manufacturing jobs.
Teva Pharmaceutical Industries won't be joining the throng of genericsmakers are preparing to flood the market with copycat Lipitor.
The Indian generics company is bringing in a couple of hired guns to tell it what improvements are left to be made.
The drugmaker teamed up with EatingWell magazine to develop a mobile app, dubbed Recipes 2 Go, and a sister website, lipitorsmartliving.com. The mobile app hooks into Pfizer's Lipitor co-pay card offer with a feature that makes refills easier.
In a fascinating look at one aspect of pharma pricing, Forbes' Matthew Herper explores the area of rebates, providing a chart of the biggest givebacks.
When Lipitor's first copycats were unleashed, Pfizer manned the battlements. As The Wall Street Journal reports, that battle is over.
Just how important resolving manufacturing problems can be to a drugmaker's upside was evident in the skyrocketing first-quarter earnings of Ranbaxy Laboratories.
Ranbaxy Laboratories' first-quarter earnings soared on its launch of the cholesterol drug copycat.
Pfizer's mission to expand Lyrica use just hit a couple of roadblocks.